ClinicalTrials.gg
CompletedNCT03314740BAROCCOUpdated Jan 10, 2025Results posted

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

A Phase 2 interventional study of Paclitaxel and Cediranib in Ovarian Neoplasms, sponsored by Mario Negri Institute for Pharmacological Research. Completed at 6 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Mario Negri Institute for Pharmacological Research · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing cediranib in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. cediranib · Ovarian Neoplasms.

Enrollment
6th of 16
123 · median 66
Started
2017
with 3 others
Phase 2
7 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
1 of 16
Mario Negri Institute for Pharmacological Research

Among the 16 studies testing cediranib in Ovarian Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 7 in phase 2, and was the 13th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 16 studies testing cediranib in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About cediranib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing cediranib in Ovarian Neoplasms as a file.
02

Study summary

This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian cancer.

Patients will be randomised in a 1:1:1 ratio to three treatment arms:

  • Arm A: Paclitaxel 80 mg/mq every week
  • Arm B: Cediranib 20 mg/day + Olaparib 600 mg / day (i.e. 300 mg BD) given every day
  • Arm C: Cediranib 20 mg/day given 5 days per weeks + Olaparib 600 mg / day (i.e. 300 mg BD) given 7 days per weeks
Read the detailed description

Both the experimental arms (Arm B and C) will be compared with Arm A in terms of PFS.

If both superior to the control (Arm A), they will be compared in terms of gastrointestinal safety.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients affected by confirmed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  2. /progressive disease within 6 months from last platinum-based chemotherapy (platinum resistant/refractory disease).
  3. Any (after the first).
  4. Any "last" chemotherapy line, including Paclitaxel, that should have been administered at least 6 months before the study beginning.
  5. Patients must be women > 18 years of age.
  6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • ≥ 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomization - (ANC) ≥ 1.5 x 109/L
    • White blood cells (WBC) > 3x109/L
    • count ≥ 100 x 109/L
    • Total ≤ 1.5 x institutional (ULN)
    • (SGOT)/ALT (SGPT) ≤ 2.5 x institutional Upper Limit of Normal, unless liver are present in which case it must be ≤ 5x ULN
    • estimated using the Cockcroft-Gault equation ≥51 mL/min,.
  7. performance status 0-1.
  8. Patients must have a ≥ 16 weeks.
  9. Evidence of non-childbearing status for women of (negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1 or women. Postmenopausal status is defined as:

    • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    • LH and FSH levels in the post-menopausal range for women under 50
    • Radiation-induced oophorectomy with last menses >1 year ago,
    • Chemotherapy-induced menopause with >1 year interval since last menses
    • Surgical sterilization (bilateral oophorectomy or hysterectomy)
  10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations including follow up.
  11. At least one lesion (measurable as defined by 1.1) that can be accurately assessed by CT scan or MRI with Chest X-ray at baseline and follow up visits.
  12. BRCA1-2 mutation status known. In case of BRCA status unknown, the BRCA test must be performed before the randomization or, if not feasible, within the end-of the study treatment.
  13. Provision of prior to any study specific procedures. In case of patients unable to give written informed consent, is necessary to have the subject or legal representative sign, but in any case a witness must be present and sign and date with the person providing informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Any previous treatment with a PARP inhibitor, including Olaparib.
  2. Prior treatment with Cediranib (previous bevacizumab or other antiangiogenic drugs are allowed)
  3. Previous progression to weekly Paclitaxel
  4. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years
  5. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive bisphosphonates for bone , before and during the study as long as these were started at least 4 weeks prior to treatment with study drug.
  6. Concomitant use of known strong inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting Olaparib is 2 weeks.
  7. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting Olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  8. Persistent toxicities (>= grade 2) with the exception of alopecia, caused by previous cancer therapy.
  9. Resting with > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
  10. Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein \< 1.5g in a 24 hr period or urine protein/creatinine ratio \< 1.5.
  11. A history of poorly controlled hypertension or resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy (measurements will be made after the patient has been resting supine for a minimum of 5 minutes. Two or more readings should be taken at 2-minute intervals and averaged. If the first two diastolic readings differ by more than 5 mmHg, then an additional reading should be obtained and averaged).
  12. Blood transfusions within 28 days prior to study start.
  13. Features suggestive of Myelodysplastic syndrome or Acute myeloid leukemia (MDS/AML) on peripheral blood smear.
  14. Patients with symptomatic uncontrolled . A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of before and during the study as long as these were started at least 28 days prior to treatment.
  15. Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  16. Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining .
  17. Patients unable to swallow medications and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  18. Breast feeding women.
  19. patients, e.g., patients who are known to be serologically positive for (HIV) and are receiving antiviral therapy.
  20. Patients with known active hepatic disease (i.e., or C).
  21. Patients with a known to Olaparib, Cediranib or any of the of the products.
  22. Patients with a known hypersensitivity to Paclitaxel.
  23. Patients with uncontrolled seizures.
  24. History of abdominal fistula or gastrointestinal perforation.
  25. Prior gastrectomy.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    Arm A

    Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.

    Drug: Paclitaxel

  • Experimental
    Arm B

    Oral administration of two experimental drugs: * Cediranib 20 mg/day given 7 days per week * Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death.

    Drug: Cediranib · Drug: Olaparib

  • Experimental
    Arm C

    Oral administration of two experimental drugs: * Cediranib 20 mg/day given 5 days per week * Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death.

    Drug: Cediranib · Drug: Olaparib

Interventions

  • Comparator active compound

    Also known as: chemotherapy

  • Experimental compound

    Also known as: tyrosine kinase inhibitor

  • Experimental compound

    Also known as: Parp inihibitor

06

What researchers measure

Primary outcomes

  1. Efficacy: Progression Free Survival (PFS)

    PFS is defined as time from randomization to the date of first progression or death for any cause, whichever comes first. Progression was established as the radiological disease progression according to RECIST 1.1 (as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions") or to clinical assessment in case radiological evaluation is not feasible due to clinical condition.

    Time frame: An average of 30 months for each participant

  2. Safety: Number of Evacuations Per Day

    Number of evacuations per day used as an index of gastro-intestinal toxicity profile of experimental drugs

    Time frame: Evacuation were collected daily for the first four weeks of treatment of experimental drugs

Secondary outcomes

  1. Efficacy: Objective Response Rate (ORR)

    Percentage of patients with an objective response as determined by RECIST 1.1

    Time frame: Disease assessments were scheduled every 8 weeks (+/- 1 week) from randomization for all treatment duration (an average of 3.5 months).

  2. Efficacy: PFS2

    PFS2 is defined as time from first progression to the date of second progression or death for any cause, whichever comes first.

    Time frame: Up to one year after the last patient enrolled

  3. Efficacy: Overall Survival (OS)

    OS is defined as time from randomization to the date of death for any cause

    Time frame: Up to one year after the last patient enrolled

  4. Efficacy: Quality of Life

    Quality of Life evaluated by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire

    Time frame: Up to sixth month of study treatment

  5. Safety: Maximum Toxicity Grade

    Maximum toxicity grade experienced by each patient, for each toxicity, according to NCI-CTCAE v. 4.03

    Time frame: Up to 30 days after the end of treatment

  6. Safety: Number of Patients Experiencing Grade 3-4 Toxicity for Each Toxicity

    Number of patients experiencing grade 3-4 toxicity for each toxicity according to NCI-CTCAE v. 4.03

    Time frame: Adverse events were collected at the end of each cycle for the duration of treatment for each participant (an average of 3.5 months) and following 30 days after the end of treatment.

  7. Safety: Type, Frequency and Nature of SAEs

    Type, frequency and nature of SAEs, according to NCI-CTCAE v. 4.03

    Time frame: Up to 30 days after the end of treatment

  8. Safety: Number of Patients With at Least a SAE; Patients With at Least a SADR

    Number of patients with at least a SAE; patients with at least a SADR, according to NCI-CTCAE v. 4.03

    Time frame: Up to 30 days after the end of treatment

  9. Safety: Number of Patients With at Least a SUSAR

    Number of patients with at least a SUSAR, according to NCI-CTCAE v. 4.03

    Time frame: Up to 30 days after the end of treatment

  10. Compliance: Number of Administered Cycles

    The endpoint for compliance is the number of administered cycles.

    Time frame: Up to one year after the last patient enrolled

  11. Compliance: Reasons for Discontinuation and Treatment Modification

    The endpoints for compliance are the reasons for discontinuation and treatment modification.

    Time frame: Up to one year after the last patient enrolled

  12. Compliance: Dose Intensity

    Entire dose administered during treatment

    Time frame: Up to one year after the last patient enrolled

07

Results

Posted Jan 10, 2025

Participant flow

The study was approved and activated in 7 experimental sites. The enrolment was closed on 18th October 2018 with the inclusion of 123 patients.

Participant flow — Overall Study
MilestoneArm AArm BArm C
Started414141
Completed414141
Not completed000

Outcome measures

PrimaryEfficacy: Progression Free Survival (PFS)

PFS is defined as time from randomization to the date of first progression or death for any cause, whichever comes first. Progression was established as the radiological disease progression according to RECIST 1.1 (as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions") or to clinical assessment in case radiological evaluation is not feasible due to clinical condition.

Time frame:
An average of 30 months for each participant
Reported as:
Median · months
Efficacy: Progression Free Survival (PFS)
monthsArm AArm BArm C
Efficacy: Progression Free Survival (PFS)3.1 (1.9 to 6.3)5.6 (3.2 to 7.4)3.8 (2.0 to 5.8)
Statistical analysis
  • Arm A vs Arm B · cox model · p = 0.265 · Hazard ratio (hr): 0.76 · 90% CI 0.5 to 1.14
  • Arm A vs Arm C · cox- model · p = 0.904 · Hazard ratio (hr): 1.03 · 90% CI 0.68 to 1.55
PrimarySafety: Number of Evacuations Per Day

Number of evacuations per day used as an index of gastro-intestinal toxicity profile of experimental drugs

Time frame:
Evacuation were collected daily for the first four weeks of treatment of experimental drugs

No measurements were reported for this outcome.

SecondaryEfficacy: Objective Response Rate (ORR)

Percentage of patients with an objective response as determined by RECIST 1.1

Time frame:
Disease assessments were scheduled every 8 weeks (+/- 1 week) from randomization for all treatment duration (an average of 3.5 months).
Reported as:
Number · participants
Efficacy: Objective Response Rate (ORR)
participantsArm AArm BArm C
Efficacy: Objective Response Rate (ORR)964
SecondaryEfficacy: PFS2

PFS2 is defined as time from first progression to the date of second progression or death for any cause, whichever comes first.

Time frame:
Up to one year after the last patient enrolled

Results for this outcome have not been posted.

SecondaryEfficacy: Overall Survival (OS)

OS is defined as time from randomization to the date of death for any cause

Time frame:
Up to one year after the last patient enrolled

Results for this outcome have not been posted.

SecondaryEfficacy: Quality of Life

Quality of Life evaluated by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire

Time frame:
Up to sixth month of study treatment

Results for this outcome have not been posted.

SecondarySafety: Maximum Toxicity Grade

Maximum toxicity grade experienced by each patient, for each toxicity, according to NCI-CTCAE v. 4.03

Time frame:
Up to 30 days after the end of treatment

Results for this outcome have not been posted.

SecondarySafety: Number of Patients Experiencing Grade 3-4 Toxicity for Each Toxicity

Number of patients experiencing grade 3-4 toxicity for each toxicity according to NCI-CTCAE v. 4.03

Time frame:
Adverse events were collected at the end of each cycle for the duration of treatment for each participant (an average of 3.5 months) and following 30 days after the end of treatment.
Reported as:
Count of participants · Participants
Safety: Number of Patients Experiencing Grade 3-4 Toxicity for Each Toxicity
ParticipantsArm AArm BArm C
Anemia grade≥3046
Bone marrow hypocellular grade≥3010
Febrile neutropenia grade≥3001
Diarrhea grade≥3021
Mucositis oral grade≥3010
Nausea grade≥3013
Vomiting grade≥3002
Fatigue grade≥3045
Sepsis grade 5100
Neutrophil count decreased grade≥3211
Platelet count decreased grade≥3010
White blood cells decreased grade≥3100
Anorexia grade≥3010
Myelodysplastic syndrome grade 5010
Peripheral motor neuropathy grade≥3100
Pneumonitis grade≥3010
Palmar-plantar erythrodysesthesia syndrome grade≥3010
Hypertension grade≥3056
Thromboembolic event grade≥3001
SecondarySafety: Type, Frequency and Nature of SAEs

Type, frequency and nature of SAEs, according to NCI-CTCAE v. 4.03

Time frame:
Up to 30 days after the end of treatment

Results for this outcome have not been posted.

SecondarySafety: Number of Patients With at Least a SAE; Patients With at Least a SADR

Number of patients with at least a SAE; patients with at least a SADR, according to NCI-CTCAE v. 4.03

Time frame:
Up to 30 days after the end of treatment

Results for this outcome have not been posted.

SecondarySafety: Number of Patients With at Least a SUSAR

Number of patients with at least a SUSAR, according to NCI-CTCAE v. 4.03

Time frame:
Up to 30 days after the end of treatment

Results for this outcome have not been posted.

SecondaryCompliance: Number of Administered Cycles

The endpoint for compliance is the number of administered cycles.

Time frame:
Up to one year after the last patient enrolled

Results for this outcome have not been posted.

SecondaryCompliance: Reasons for Discontinuation and Treatment Modification

The endpoints for compliance are the reasons for discontinuation and treatment modification.

Time frame:
Up to one year after the last patient enrolled

Results for this outcome have not been posted.

SecondaryCompliance: Dose Intensity

Entire dose administered during treatment

Time frame:
Up to one year after the last patient enrolled

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were collected at the end of each cycle for the duration of treatment for each participant (an average of 3.5 months) and following 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A24/28 (85.7%)3/28 (10.7%)16/28 (57.1%)
Arm B31/41 (75.6%)11/41 (26.8%)36/41 (87.8%)
Arm C34/41 (82.9%)9/41 (22%)34/41 (82.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventArm AArm BArm C
Intestinal obstructionGastrointestinal disorders0/283/415/41
AscitesGastrointestinal disorders2/280/410/41
Thromboembolic eventVascular disorders1/280/411/41
SepsisInfections and infestations1/280/410/41
abdomina painGastrointestinal disorders0/280/411/41
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/280/411/41
AnaemiaBlood and lymphatic system disorders0/280/411/41
AstheniaGeneral disorders0/280/411/41
Atrial fibrillationCardiac disorders0/281/410/41
Biliary obstructionHepatobiliary disorders0/281/410/41
Most frequent other events
Most frequent other events
EventArm AArm BArm C
NauseaGastrointestinal disorders6/2824/4122/41
FatigueGeneral disorders9/2821/4117/41
VomitingGastrointestinal disorders1/2818/4117/41
AnemiaBlood and lymphatic system disorders9/286/419/41
HypertensionVascular disorders1/2813/419/41
DiarrheaGastrointestinal disorders2/286/413/41
Neutrophil count decreasedInvestigations3/283/412/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BArm CTotal
Mean62.6 ± 8.161.0 ± 11.461.4 ± 9.461.7 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BArm CTotal
Female414141123
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BArm CTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White363840114
More than one race0000
Unknown or Not Reported4206
Previous Chemotherapy lines
Previous Chemotherapy lines(lines)Arm AArm BArm CTotal
Mean2.6 ± 1.23.1 ± 1.52.9 ± 1.22.9 ± 1.3
BRCA mutated
BRCA mutated(Participants)Arm AArm BArm CTotal
Count of participants47415
Last Platinum Free interval
Last Platinum Free interval(months)Arm AArm BArm CTotal
Mean3.0 ± 2.32.5 ± 1.92.3 ± 2.42.6 ± 2.2
08

Study locations

6 sites
  • Spedali Civili di Brescia
    Brescia, BS 25123, Italy
  • Ospedale San Gerardo - ASST Monza
    Monza, MB 20900, Italy
  • Istituto Oncologico Veneto (IOV)
    Padova, PD 35128, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, RE 42123, Italy
  • Policlinico Umberto I - Università La Sapienza
    Rome, RM 00161, Italy
  • Istituto Eurpeo di Oncologia (IEO)
    Milano, 20141, Italy
09

References and documents

Publications

  • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PubMed 35170751 ↗
  • Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. PubMed 35063281 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Apr 2021, 45 months.

Results were first posted in Jan 2025, 3 years 9 months after primary completion.

Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 45 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Oct 19, 2017
StartActual
Jun 12, 2017
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 1, 2021
Results first posted
Jan 10, 2025
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03314740
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2017
Start date
Jun 12, 2017
Primary completion
Apr 1, 2021
Completion
Apr 1, 2021
Results posted
Jan 10, 2025
Last update
Jan 10, 2025

Study contacts

Roldano Fossati, MD
study director · Mario Negri Institute for Pharmacological Research
Nicoletta Colombo, MD
principal investigator · European Institute of Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cediranib

Start the discussion